» Articles » PMID: 28589080

Radiation-Induced Oral Mucositis

Overview
Journal Front Oncol
Specialty Oncology
Date 2017 Jun 8
PMID 28589080
Citations 133
Authors
Affiliations
Soon will be listed here.
Abstract

Radiation-induced oral mucositis (RIOM) is a major dose-limiting toxicity in head and neck cancer patients. It is a normal tissue injury caused by radiation/radiotherapy (RT), which has marked adverse effects on patient quality of life and cancer therapy continuity. It is a challenge for radiation oncologists since it leads to cancer therapy interruption, poor local tumor control, and changes in dose fractionation. RIOM occurs in 100% of altered fractionation radiotherapy head and neck cancer patients. In the United Sates, its economic cost was estimated to reach 17,000.00 USD per patient with head and neck cancers. This review will discuss RIOM definition, epidemiology, impact and side effects, pathogenesis, scoring scales, diagnosis, differential diagnosis, prevention, and treatment.

Citing Articles

Radioprotection of healthy tissue via nanoparticle-delivered mRNA encoding for a damage-suppressor protein found in tardigrades.

Kirtane A, Bi J, Rajesh N, Tang C, Jimenez M, Witt E Nat Biomed Eng. 2025; .

PMID: 40011582 DOI: 10.1038/s41551-025-01360-5.


Comparative evaluation of the efficacy of herbal and benzydamine mouthwashes in preventing radiation-induced oral mucositis among head and neck cancer patients: a systematic review and network meta-analysis.

Mohandas R, Mohapatra S Evid Based Dent. 2025; .

PMID: 39948159 DOI: 10.1038/s41432-025-01117-8.


Application of Corticosteroids in Dentistry: A Review.

Satpathi S, Rathod Y, Rajpari K, Kandlikar R, Kumar Y, Gachake A J Pharm Bioallied Sci. 2025; 16(Suppl 4):S3034-S3036.

PMID: 39926827 PMC: 11805109. DOI: 10.4103/jpbs.jpbs_870_24.


Effect of Dendrobium Officinale on Radioactive Oral Mucositis of Nasopharyngeal Carcinoma and Changes of Oral Microecology.

Yang J, Liu Y, Yao H, Sun M, Tong Y, Ma G Integr Cancer Ther. 2025; 24():15347354251313524.

PMID: 39811879 PMC: 11733883. DOI: 10.1177/15347354251313524.


Causes and management of acute oncological pain: a narrative review.

Laycock H, Ramdin C, Grayer J, Brown M Anaesthesia. 2025; 80 Suppl 2():95-105.

PMID: 39777687 PMC: 11744419. DOI: 10.1111/anae.16512.


References
1.
Kono T, Kaneko A, Matsumoto C, Miyagi C, Ohbuchi K, Mizuhara Y . Multitargeted effects of hangeshashinto for treatment of chemotherapy-induced oral mucositis on inducible prostaglandin E2 production in human oral keratinocytes. Integr Cancer Ther. 2014; 13(5):435-45. DOI: 10.1177/1534735413520035. View

2.
Wagner W, Prott F, Schonekas K . Amifostine: a radioprotector in locally advanced head and neck tumors. Oncol Rep. 1998; 5(5):1255-7. DOI: 10.3892/or.5.5.1255. View

3.
Kim J, Baker D, Hahn S, Goodchild N, Constable W . Topical use of N-acetylcysteine for reduction of skin reaction to radiation therapy. Semin Oncol. 1983; 10(1 Suppl 1):86-92. View

4.
LEBORGNE J, LEBORGNE F, Zubizarreta E, Ortega B, MEZZERA J . Corticosteroids and radiation mucositis in head and neck cancer. A double-blind placebo-controlled randomized trial. Radiother Oncol. 1998; 47(2):145-8. DOI: 10.1016/s0167-8140(97)00174-6. View

5.
Bardet E, Martin L, Calais G, Tuchais C, Bourhis J, Rhein B . Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol. 2003; 29(6 Suppl 19):57-60. DOI: 10.1053/sonc.2002.37348. View